{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T15:31:54Z","timestamp":1648827114623},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1097\/ftd.0b013e318299920a","type":"journal-article","created":{"date-parts":[[2013,11,21]],"date-time":"2013-11-21T09:16:53Z","timestamp":1385025413000},"page":"863-866","source":"Crossref","is-referenced-by-count":0,"title":["An Audit of a Therapeutic Drug Monitoring Service for Allopurinol Therapy"],"prefix":"10.1097","volume":"35","author":[{"given":"Diluk R. W.","family":"Kannangara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheena N.","family":"Ramasamy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John E.","family":"Ray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graham","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Garry G.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth M.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard O.","family":"Day","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-19-20210129","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1111\/j.1445-5994.2012.02794.x","article-title":"A systematic review of the prevalence of gout and hyperuricaemia in Australia.","volume":"42","author":"Robinson","year":"2012","journal-title":"Intern Med J"},{"key":"R2-19-20210129","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2165\/00003088-200746080-00001","article-title":". Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol.","volume":"46","author":"Day","year":"2007","journal-title":"Clin Pharmacokinet"},{"key":"R3-19-20210129","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","article-title":". EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).","volume":"65","author":"Zhang","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"R4-19-20210129","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/rheumatology\/kem056a","article-title":". British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout.","volume":"46","author":"Jordan","year":"2007","journal-title":"Rheumatology"},{"key":"R5-19-20210129","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","article-title":". 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia.","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res"},{"key":"R6-19-20210129","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1177\/106002809302700317","article-title":"Allopurinol hypersensitivity syndrome: a review.","volume":"27","author":"Arellano","year":"1993","journal-title":"Ann Pharmacother"},{"key":"R7-19-20210129","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/art.1780290111","article-title":"The allopurinol hypersensitivity syndrome. Unnecessary morbidity and mortality.","volume":"29","author":"Singer","year":"1986","journal-title":"Arthritis Rheum"},{"key":"R8-19-20210129","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.jid.5701033","article-title":". Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study.","volume":"128","author":"Mockenhaupt","year":"2008","journal-title":"J Invest Dermatol"},{"key":"R9-19-20210129","first-page":"411","article-title":"Anderson J, et al..","volume":"42","author":"Lee","year":"2012","journal-title":"Initiating allopurinol therapy: do we need to know the patients human leucocyte antigen status Intern Med J"},{"key":"R10-19-20210129","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","article-title":"Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency.","volume":"76","author":"Hande","year":"1984","journal-title":"Am J Med"},{"key":"R11-19-20210129","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/rheumatology\/26.6.445","article-title":". Plasma oxipurinol concentrations during allopurinol therapy.","volume":"26","author":"Emmerson","year":"1987","journal-title":"Br J Rheumatol"},{"key":"R12-19-20210129","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/clpt.2011.113","article-title":". Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level.","volume":"90","author":"Stamp","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"R13-19-20210129","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2165\/00003088-200847020-00004","article-title":". Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects.","volume":"47","author":"Stocker","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"R15-19-20210129","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1111\/j.1365-2125.2011.04147.x","article-title":". Oxypurinol, allopurinol and allopurinol-1-riboside in plasma following an acute overdose of allopurinol in a patient with advanced chronic kidney disease.","volume":"73","author":"Kannangara","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"R17-19-20210129","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1365-2125.2012.04207.x","article-title":". The pharmacokinetics of oxypurinol in people with gout.","volume":"74","author":"Stocker","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"R18-19-20210129","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1007\/s00228-013-1478-8","article-title":". The population pharmacokinetics of allopurinol and oxypurinol in patients with gout.","volume":"69","author":"Wright","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"R19-19-20210129","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1002\/art.34488","article-title":". Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol.","volume":"64","author":"Stamp","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R20-19-20210129","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/art.30119","article-title":". Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment.","volume":"63","author":"Stamp","year":"2011","journal-title":"Arthritis Rheum"},{"key":"R21-19-20210129","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/RHU.0b013e318164dceb","article-title":"Higher therapeutic plasma oxypurinol concentrations might be required for gouty patients with chronic kidney disease.","volume":"14","author":"Panomvana","year":"2008","journal-title":"J Clin Rheumatol"},{"key":"R22-19-20210129","first-page":"1646","article-title":". Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout.","volume":"33","author":"Dalbeth","year":"2006","journal-title":"J Rheumatol"},{"key":"R23-19-20210129","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1073\/pnas.0409500102","article-title":". HLA-B5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol.","volume":"102","author":"Hung","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R24-19-20210129","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/archinte.1974.00320210163026","article-title":"Severe allopurinol hypersensitivity. Association with thiazides and prior renal compromise.","volume":"134","author":"Young","year":"1974","journal-title":"Arch Intern Med"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0b013e318299920a","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:41:08Z","timestamp":1620952868000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201312000-00019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0b013e318299920a","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]}}}